Keyword: Charles Grassley
Why didn't Medicaid officials go after Mylan for underpaying EpiPen rebates—and just how much did those years of underpayments cost the government?
Mylan has been fighting for more than a year to block Teva’s generic EpiPen. But all along EpiPen itself has been classified as a generic drug for Medicaid patients--and now, U.S. senators are calling on the Justice Department to find out why.
Mylan CEO Heather Bresch will tell congressional critics Wednesday that she “never expected” to face questions about EpiPen prices. But as the public outcry shows, those expectations were way off--and she'll face questions aplenty at today's hearing on Capitol Hill.
The power of a Hillary Clinton tweet showed again Wednesday, when the presidential candidate spoke on drug price, raising fears of government action. Biotech stocks, pharma stocks--even U.K. drugmakers suffered.
Amid a frenzy of criticism for the price of EpiPen, Mylan swiftly expanded its co-pay help for patients. But it did not adjust the actual price of a med that’s more than 400% more expensive than it was in 2009.
Mylan is facing the prospect of investigations--as well as public criticism--following years of price increases on its big-selling EpiPen.